Glenmark Pharmaceuticals receives ANDA approval for Nicardipine Hydrochloride Capsules, 20 mg and 30 mg

Glenmark Pharmaceuticals Limited (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Nicardipine Hydrochloride Capsules, 20 mg and 30 mg, the generic version of Cardene® Capsules, 20 mg and 30 mg, of Chiesi USA, Inc. Glenmark's Nicardipine Hydrochloride Capsules, 20 mg and 30 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.

According to IQVIATM sales data for the 12-month period ending October 2022, the Cardene® Capsules, 20 mg and 30 mg market achieved annual sales of approximately $10.9 million*.

Glenmark's current portfolio consists of 178 products authorized for distribution in the U.S. marketplace and 46 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 417.70 as compared to the previous close of Rs. 436.50. The total number of shares traded during the day was 70787 in over 3195 trades.

The stock hit an intraday high of Rs. 437.00 and intraday low of 416.00. The net turnover during the day was Rs. 29939440.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 ANDAApproval USFDA NicardipineHydrochlorideCapsules Cardene